Featured Research

from universities, journals, and other organizations

Strong Evidence Of A Genetic Risk Factor For Parkinson's Disease

Date:
August 9, 2006
Source:
Mayo Clinic
Summary:
A Mayo Clinic-led international research collaboration -- one of the largest studies of its kind -- provides strong evidence that a genetic risk factor may account for 3 percent of the cause of Parkinson's disease.

A Mayo Clinic-led international research collaboration -- one of the largest studies of its kind -- provides strong evidence that a genetic risk factor may account for 3 percent of the cause of Parkinson's disease.

Related Articles


Parkinson's disease is a debilitating neurological disease that affects about 1 million people in the United States. Little is known about its causes and hence there is no cure.

"This is an important step forward because the contribution of common genetic risk factors to the development of Parkinson's has long been suspected, but the high quality of data needed to make such discoveries has been missing," says Demetrius Maraganore, M.D., Mayo Clinic neurologist and lead study investigator. "This well-designed and large study provides evidence that common genetic variants contribute to the cause of Parkinson's."

The collaboration included researchers from 11 countries. Their findings will be published in the Aug. 9 issue of the Journal of the American Medical Association (http://jama.ama-assn.org/).

In their study, the researchers analyzed clinical and genetic data from 2,692 Parkinson's disease patients and 2,652 healthy subjects who were matched to the Parkinson's patients for age and gender. Results showed that persons with longer lengths of a DNA segment that promotes the activity of a gene known as alpha-synuclein had a 1.5 times greater risk for Parkinson's disease.

Explains Dr. Maraganore, "Our study provides compelling evidence that variability in the alpha-synuclein gene is a risk factor for Parkinson's disease worldwide. The common DNA variants that increase Parkinson's disease risk cause the gene to produce too much alpha-synuclein protein in a process known as overexpression. Our findings support the development of therapies that reduce alpha-synuclein gene expression. Such therapies have the potential to prevent or delay the onset of Parkinson's disease or to halt or slow its progression."

Significance of the Research

Earlier, small studies showed that rare variations (mutations) in the alpha-synuclein gene caused Parkinson's disease in a few isolated families. Further small studies suggested that common variations in the gene, while not sufficient to cause Parkinson's, make people susceptible to the disease.

"However, the results of those small studies were inconsistent," says Dr. Maraganore. "What was lacking was a well-designed, large study to see if common variations in the alpha-synuclein gene contribute to Parkinson's risk worldwide. The current study provides this much-needed evidence. Alpha-synuclein gene variability was associated with Parkinson's disease across several populations."

About Parkinson's Disease
Parkinson's disease involves the degeneration of brain cells, particularly those that make the chemical dopamine. The disease is characterized by uncontrolled shaking (tremor), slowed movements, muscle stiffness and imbalance. While available treatments can reduce the symptoms, their benefit is short-lived. No method can prevent Parkinson's or slow or halt its progression.

Collaboration and Support
Investigators from Mayo Clinic, other U.S. medical centers and from medical centers in 10 other countries, including Australia, Belgium, France, Germany, Greece, Italy, Ireland, Norway and Singapore, participated in this research. The work was supported primarily by an Edward J. Safra Global Genetics Consortium grant of the Michael J. Fox Foundation for Parkinson's Research.

Disclosure: In accordance with the Bayh-Dole Act of 1980, Dr. Maraganore and Mayo Clinic report U.S. and foreign pending patent applications for a technology that provides diagnosis and treats neurodegenerative diseases. Mayo Clinic has licensed this technology to Alnylam Pharmaceuticals, Inc., and both Mayo Clinic and Dr. Maraganore may receive royalties from that license. Additional disclosures are detailed in the JAMA paper.


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Cite This Page:

Mayo Clinic. "Strong Evidence Of A Genetic Risk Factor For Parkinson's Disease." ScienceDaily. ScienceDaily, 9 August 2006. <www.sciencedaily.com/releases/2006/08/060809082639.htm>.
Mayo Clinic. (2006, August 9). Strong Evidence Of A Genetic Risk Factor For Parkinson's Disease. ScienceDaily. Retrieved March 5, 2015 from www.sciencedaily.com/releases/2006/08/060809082639.htm
Mayo Clinic. "Strong Evidence Of A Genetic Risk Factor For Parkinson's Disease." ScienceDaily. www.sciencedaily.com/releases/2006/08/060809082639.htm (accessed March 5, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, March 5, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Newsy (Mar. 5, 2015) A survey of Boston mothers and toddlers found that 15 percent of two-year-olds drink coffee and 2.5 percent of 1-year-olds. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins